中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2013年
10期
1031-1035,1040
,共6页
陆幸妍%李青南%吴飞虎%罗文寅%杨国柱%陈珺%卢丽%金勋杰
陸倖妍%李青南%吳飛虎%囉文寅%楊國柱%陳珺%盧麗%金勛傑
륙행연%리청남%오비호%라문인%양국주%진군%로려%금훈걸
重组人骨形成蛋白-2%重组人表皮生长因子%联合用药%成骨细胞%跖骨增长
重組人骨形成蛋白-2%重組人錶皮生長因子%聯閤用藥%成骨細胞%蹠骨增長
중조인골형성단백-2%중조인표피생장인자%연합용약%성골세포%척골증장
rhBMP2%rhVEGF%Drug combination%osteoblast%Metatarsal growth
目的：观察rhBMP2（重组人骨形成蛋白-2）与rhVEGF（重组人表皮生长因子）联合用药对体外培养SD大鼠成骨细胞不同成熟阶段的增殖、分化及胎鼠跖骨生长的影响。方法分离新生大鼠颅盖骨的细胞培养获得前成骨细胞（ preosteoblast ， pOB），再诱导分化为成骨细胞（osteoblast，OB），以rhBMP2和低（2μg/L）、中（4μg/L）及高（8μg/L）剂量rhVEGF干预48 h，比较乳酸脱氢酶（ LDH）活性、细胞相对增殖率（ RGR）和碱性磷酸酶（ AKP）活性。另取胎鼠跖骨，以rhBMP2和rhVEGF干预7 d和14 d，比较其纵向骨生长率（ longitudinal bone growth rate ，LBDR）。结果①LDH组间差异无统计学意义。②RGR：pOB的中、高剂量联用组较同剂量rhBMP2组高。 OB的中、高剂量联用组较同剂量rhBMP2及rhVEGF组高。③AKP：pOB的中、高剂量联用组较同剂量rhBMP2及rhVEGF组高。 OB的组间差异无统计学意义。④LBDR；7d联用组较rhBMP2及rhVEGF组高，但14d联用组差异无统计学意义。结论适量联用rhBMP2与rhVEGF对骨再生诱导及骨组织早期生长有协同促进效应。
目的：觀察rhBMP2（重組人骨形成蛋白-2）與rhVEGF（重組人錶皮生長因子）聯閤用藥對體外培養SD大鼠成骨細胞不同成熟階段的增殖、分化及胎鼠蹠骨生長的影響。方法分離新生大鼠顱蓋骨的細胞培養穫得前成骨細胞（ preosteoblast ， pOB），再誘導分化為成骨細胞（osteoblast，OB），以rhBMP2和低（2μg/L）、中（4μg/L）及高（8μg/L）劑量rhVEGF榦預48 h，比較乳痠脫氫酶（ LDH）活性、細胞相對增殖率（ RGR）和堿性燐痠酶（ AKP）活性。另取胎鼠蹠骨，以rhBMP2和rhVEGF榦預7 d和14 d，比較其縱嚮骨生長率（ longitudinal bone growth rate ，LBDR）。結果①LDH組間差異無統計學意義。②RGR：pOB的中、高劑量聯用組較同劑量rhBMP2組高。 OB的中、高劑量聯用組較同劑量rhBMP2及rhVEGF組高。③AKP：pOB的中、高劑量聯用組較同劑量rhBMP2及rhVEGF組高。 OB的組間差異無統計學意義。④LBDR；7d聯用組較rhBMP2及rhVEGF組高，但14d聯用組差異無統計學意義。結論適量聯用rhBMP2與rhVEGF對骨再生誘導及骨組織早期生長有協同促進效應。
목적：관찰rhBMP2（중조인골형성단백-2）여rhVEGF（중조인표피생장인자）연합용약대체외배양SD대서성골세포불동성숙계단적증식、분화급태서척골생장적영향。방법분리신생대서로개골적세포배양획득전성골세포（ preosteoblast ， pOB），재유도분화위성골세포（osteoblast，OB），이rhBMP2화저（2μg/L）、중（4μg/L）급고（8μg/L）제량rhVEGF간예48 h，비교유산탈경매（ LDH）활성、세포상대증식솔（ RGR）화감성린산매（ AKP）활성。령취태서척골，이rhBMP2화rhVEGF간예7 d화14 d，비교기종향골생장솔（ longitudinal bone growth rate ，LBDR）。결과①LDH조간차이무통계학의의。②RGR：pOB적중、고제량련용조교동제량rhBMP2조고。 OB적중、고제량련용조교동제량rhBMP2급rhVEGF조고。③AKP：pOB적중、고제량련용조교동제량rhBMP2급rhVEGF조고。 OB적조간차이무통계학의의。④LBDR；7d련용조교rhBMP2급rhVEGF조고，단14d련용조차이무통계학의의。결론괄량련용rhBMP2여rhVEGF대골재생유도급골조직조기생장유협동촉진효응。
Objectives To observe the effect of rhBMP2 (recombinate human bone morphogenetic protein-2) combined with rhVEGF ( recombinate human vascular endothelial growth factor ) on the osteoblast proliferation and differentiation and the metatarsal growth in SD rats in vitro.Methods Cells were isolated enzymatically from the cranium of newborn rats .The pre-osteoblasts (pOBs) were cultured and then induced into the osteoblasts (OBs).Then, the cells were cultured with rhBMP-2 (300μg· L-1) and/or rhVEGF in low dose (2 μg· L-1 ), middle dose (4 μg· L-1 ), and high dose (8 μg· L-1 ) for 48h, respectively.The lactate dehydrogenase (LDH) activity, cell relative growth rate (RGR), and alkaline phosphatase (AKP) activity were determined.The metatarsal collected from the SD fetal rats were intervened by rhBMP-2 and/or rhVEGF for 7 days or 14 days.The longitudinal bone growth rate (LBDR) was determined .Results No significant difference of LDH activity among groups was observed .RGR in the middle-and high-dose combined medication groups increased compared with that in the same dose or rhBMP 2 group for pOBs .The results were the same in the middle-and high-dose combined medication groups compared with that in the same dose of rhBMP 2 group and rhVEGF group for OBs.The activity of AKP increased in the middle-and high-dose combined medication groups compared with that in the same dose of rhBMP2 group and rhVEGF group for pOBs , but no significant difference was observed for OBs .LBDR increased significantly in combined medication group of 7-day culturing compared with that in the rhBMP 2 and rhVEGF group , but no significant difference was observed in 14-day culturing .Conclusion The combination of proper dose of rhBMP 2 and rhVEGF can promote osteoblastic generation and bone tissue growth at the early stage in a synergic way .
